21757-13-1

Upstream product

• 100-66-3 methoxybenzene 
• 120-44-5 1,4-di(4-methoxyphenyl)ethanone 
• 2632-13-5 2-Bromo-4'-methoxyacetophenone 

Downstream Products

• 1350308-50-7 1-propyl-2,3,5-tris(4-methoxyphenyl)-1H-pyrrole 
• 1350308-71-2 1-methyl-2,3,5-tris(4-hydroxyphenyl)-1H-pyrrole 
• 1350308-73-4 1-ethyl-2,3,5-tris(4-hydroxyphenyl)-1H-pyrrole 
• 1350308-75-6 1-propyl-2,3,5-tris(4-hydroxyphenyl)-1H-pyrrole 
• 1350308-76-7 1-(2-methylpropyl)-2,3,5-tris(4-hydroxyphenyl)-1H-pyrrole 
• 1350308-57-4 1-(2-methylpropyl)-2,3,5-tris(4-methoxyphenyl)-1H-pyrrole 
• 1350308-46-1 1-ethyl-2,3,5-tris(4-methoxyphenyl)-1H-pyrrole 
• 1314125-84-2 2,3,5-tris(4-methoxyphenyl)-1-methyl-1H-pyrrole 

Relevant academic research and scientific papers

Development of 2,3,5-triaryl-1H-pyrroles as estrogen receptorα selective ligands

1-Alkyl-2,3,5-triaryl-1H-pyrroles (for which alkyl=methyl, ethyl, n-propyl, or 2-methylpropyl) were tested for stability, estrogen receptor (ER) binding, and inhibition of tumor cell growth. These pyrroles (typeB) showed higher stability in aqueous solution than their 1,2,4-triaryl-1H-pyrrole congeners (typeA pyrroles), exclusive ERα binding (no ERβ interaction), and a hormonal profile of partial agonists at ERα. The most potent compound, 1-(2-methylpropyl)-2,3,5-tris(4-hydroxyphenyl)-1H-pyrrole (5d), was less active than the lead structure 1,3,5-tris(4-hydroxyphenyl)-4-propyl-1H-pyrazole (PPT) in MCF-7 cells stably transfected with the plasmid EREwtcluc (MCF-7/2a), but more potent in U2-OS/α cells. Furthermore, 5d showed weak anti-estrogenic properties (IC50=310nM). An additional propyl chain at C4 decreased the stability and pharmacological effects.